EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Biochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals

Maram Marei, Nefertiti El-Nikhely, Eman Sheta iD, Hanan Ragab, Ahmed Wahid, Hesham Saeed, Sherif A F Rostom

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s512058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Maram Marei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, 21521, Egypt. Hauptthemen laut MEDLINE: Celecoxib, Pyrazoles, Chemical and Drug Induced Liver Injury, Cyclooxygenase 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Liver fibrosis is a life-threatening disease that greatly impacts the morbidity and mortality of hepatic patients worldwide, resulting mainly as a consequence of hepatitis C, alcoholic and non-alcoholic fatty liver. COX-1 and COX-2 isozymes catalyze the synthesis of prostaglandins (PGs) and thromboxanes (TXs) from arachidonic acid causing inflammation. Owing to the scarcity of approved fibrolytic drugs available for human use, celecoxib (a selective COX-2 inhibitor) has been repurposed as a potential antifibrotic and fibrolytic agent in some chronic liver fibrosis models.

Methods

The present study aims to discover a non-invasive treatment for liver fibrosis through investigating the possible ability of three celecoxib-related bipyrazole compounds HR1-3 to reverse chemically induced liver fibrosis in rats using CCl4. This fibrolytic effect was verified by histopathological, immunohistochemical, biochemical and biomolecular assays. In addition, in silico computer-aided evaluation of the compounds' binding mode to certain molecular targets was performed, and the in silico physicochemical properties, drug likeness and pharmacokinetic parameters were predicted using web-based applications.

Results

The analogs HR1-3 could serve as novel therapeutic candidates for the mitigation of liver fibrosis that deserves further derivatizations and investigations. In particular, the fluorinated analog HR3 proved to be the most active member in this study when compared to celecoxib due to its distinguished histopathological and immunohistochemical investigation results, beside its antioxidant potential, as well as its reliable effects against some biomarkers, namely, MMP-9, TGF-β1, TIMP-1, IL-6 and TNF-α.

Conclusion

Based on the obtained results, the fluorinated analog HR3 could serve as a novel therapeutic candidate for the amelioration of liver fibrosis that deserves further derivatizations and investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CelecoxibPyrazolesChemical and Drug Induced Liver InjuryCyclooxygenase 2 InhibitorsLiver CirrhosisAnimalsRatsMaleCarbon TetrachlorideRats, WistarMolecular StructureStructure-Activity RelationshipDose-Response Relationship, Drug

Stichwörter der Autor:innen

CCl4COX2ELISART-PCRliver fibrosismolecular modeling

Substanzen

CelecoxibPyrazolesCarbon TetrachlorideCyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, 21521, Egypt.
  • Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, 21521, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.

ORCID-Profile: Eman Sheta

Zitieren

APA

Marei, M., El-Nikhely, N., Sheta, E., Ragab, H., Wahid, A., Saeed, H., & Rostom, S. A. F. (2025). Biochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s512058

Vancouver

Marei M, El-Nikhely N, Sheta E, Ragab H, Wahid A, Saeed H, et al. Biochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s512058

BibTeX
@article{Marei2025,
  author = {Marei, Maram and El-Nikhely, Nefertiti and Sheta, Eman and Ragab, Hanan and Wahid, Ahmed and Saeed, Hesham and Rostom, Sherif A F},
  title = {Biochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s512058}
}
Kostenlos starten →